Early C-reactive protein reduction predicts survival in COVID-19 severe pneumonia treated with glucocorticoids

prolonged, low-dose glucocorticoid treatment reduces systemic inflammation and mortality in patients with SARS-CoV-2-related pneumonia requiring respiratory support. Previous studies reported a significant C-reactive protein (CRP) reduction in the early days of treatment compared to placebo. While CRP is an independent predictor of severity in community-acquired pneumonia, there is no evidence on the correlation between CRP changes and mortality within a glucocorticoid-treated population.

data from the MEDEAS randomized controlled trial were re-analyzed as a single cohort of patients with SARS-CoV-2-related pneumonia undergoing either dexamethasone 6 mg/day for 10 days or methylprednisolone 80 mg/day for ≥ 8 days from hospitalization. CRP relative decrease between treatment initiation and day 3 was calculated and tested to predict 28-day mortality. Additionally, clinically relevant CRP percentage changes by day 3 were calculated and tested to predict survival. A stratification was performed for baseline PaO₂:FiO₂, and a multivariable analysis was conducted to adjust for confounders.

597 patients were included in the analysis. In multivariable logistic regression analysis, the relative decrease in CRP by day 3 was significantly associated with 28-day survival (OR 0.77; 95%CI 0.64-0.99; p = 0.011). Furthermore, a ≥ 5% CRP reduction was associated with a lower mortality compared to either < 5% reduction or any increase in CRP levels by day 3 (8.2% versus 18.5%; OR 0.40; 95%CI 0.23-0.69; p = 0.001) in the whole cohort. When stratifying for baseline PaO₂:FiO₂, a ≥ 5% CRP reduction resulted in a lower mortality (10.9% versus 28.3%; OR 0.31; 95%CI 0.16-0.61; p = < 0.001) in the more severe subgroup of patients presenting with a PaO₂:FiO₂ ≤200, while a ≥ 20% reduction was required to significantly impact on mortality among those presenting with a PaO₂:FiO₂ > 200 (3.7% versus 10.0%; OR 0.35; 95%CI 0.13-0.97; p = 0.043).

in patients with COVID-19-related severe pneumonia receiving low-dose glucocorticoid treatment, even early reductions in CRP levels, together with other meaningful clinical traits, predict survival, representing a possible biomarker to guide personalized interventions.

The MEDEAS randomized controlled trial was registered on ClinicalTrials.gov on 18 November 2020 (NCT04636671).